Melior Discovery, Inc. announced that it has entered into a collaboration with the Rett Syndrome Research Trust to screen drug-candidates in an in vivo model of Rett Syndrome.
Melior Discovery has developed world-class expertise in screening compounds for potential therapeutic activity in animal models. Melior will apply this expertise to the evaluation of large numbers of drug-candidates in a specialized model of Rett Syndrome. “This partnership is further illustration of Melior’s truly unique capabilities and competence in high throughput in vivo pharmacology,” said Andrew Reaume PhD, CEO, Melior Discovery.
Rett Syndrome, the most physically disabling of the autism spectrum disorders, strikes young girls almost exclusively, with first symptoms usually appearing before the age of 18 months. These children lose speech, motor control and functional hand use, and many suffer from seizures, orthopedic and severe digestive problems, breathing and other autonomic impairments. Most live into adulthood, and require total, around-the-clock care.
The disorder is caused by alterations of an X-linked gene, MECP2. The animal models that have been developed mimic the disorder well and provide an excellent system to test potential drug candidates.
“We are pleased to be working with Melior and have been impressed with their ability to rapidly and effectively evaluate compounds in animal models. We look forward to our collaboration as we strive to identify compounds to ameliorate the devastating symptoms of Rett,” added Monica Coenraads, Executive Director of the Rett Syndrome Research Trust.
Date: March 30, 2010
Source: Melior Discovery, Inc.
